The impact of atopic dermatitis on the daily life of patients in grossly underestimated. A study from the Charité Universität in Berlin published in the Journal of Allergy and Clinical Immunology amongst two thousand two patients and caregivers of children with moderate-to-severe atopic dermatitis showed that patients spend, on average, 1 of every 3 days in flare all year round.
The majority of patients receive prescription topical corticosteroids to treat flares; however, 49% of respondents are concerned about using these agents. On average, patients and caregivers delay initiating treatment for 7 days after onset of a flare. Only 24% of patients and caregivers feel confident they can manage atopic dermatitis flares adequately. Seventy-five percent of caregivers and patients feel that being able to effectively control atopic dermatitis would be the single most important improvement to their or their child’s quality of life.
The avoidable secondary economic cost of atopic dermatitis is estimated at €2 billion per year across the European Union.
We believe that P10 can make a difference. Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as an important pathogen that has rapidly evolved from a cause of nosocomial to community-acquired infections . Furthermore, patients treated with antibiotics quickly become recolonized, often with the same toxin-secreting organisms. Family members often serve as the source of rapid re-colonization . This is on top of the explained toxicity following prolonged exposure to antibiotics. P10 facilitates prolonged treatment without a risk for resistance development – the current bottleneck to antimicrobial treatment.
Vicious Circle underlining the role of S Aureus and MRSA in the pathogenies of atopic Dermatitis
Reference: Torsten Zuberbier, Seth J. Orlow, Amy S. Paller, Alain Taïeb, Roger Allen, José M. Hernanz-Hermosa, Jorge Ocampo-Candiani, Margaret Cox, Joanne Langeraar, Jan C. Simon (2006) The Journal of Allergy and Clinical Immunology, Vol. 118, Issue 1, Pages 226-23